Stopping hospital infections at the source.
Viropin develops decolonisation and antiseptic products that prevent MRSA and other resistant infections before they take hold.
The microbes are winning.
Antibiotics, antiseptics, and sanitisers are failing, and the replacements are failing too.
A new approach is needed.
Near-term revenue. Long-term breakthrough.
Infection Control products
MRSA nasal & topical decolonisers, pre-surgical scrubs, hospital antiseptics. Revenue pathway 24-36 months to market.
Antibiotic Restoration Therapy
Proprietary platform that disrupts bacterial resistance mechanisms, restoring the potency of existing antibiotics. IND submission planned 2028.
Existing Investment
Backed by $15M New Zealand Government R&D, multiple international patents, LOI with pharma (Tier 1 under NDA).
